Search the Newsreel

Teladoc Health (TDOC) Stock Price Cracks As BetterHelp Reset Deepens

Teladoc Health's stock price dropped over 28% after its Q2 2026 earnings report, largely due to a "reset" in its BetterHelp segment. While Integrated Care showed some positive signs, BetterHelp experienced an 11.6% revenue decline and near break-even EBITDA as it transitions from cash …

Teladoc lowers revenue outlook amid BetterHelp demand headwinds

Teladoc Health has lowered its full-year revenue outlook by 5% due to significant challenges at its mental health unit, BetterHelp. The segment experienced unexpectedly high consumer demand for its insurance offering, which it struggled to meet, causing a faster-than-anticipated decline in its cash-pay business. …

Teladoc Health (TDOC) Stock Looks Cheap Even As The Market Stays Cautious

Teladoc Health (TDOC) stock appears undervalued despite a significant 93.9% decline over the past five years. Both a Discounted Cash Flow (DCF) model and Price/Sales (P/S) ratio analysis suggest the stock is cheap compared to its intrinsic value and industry peers. The company's new …

Teladoc Health trims 2026 revenue forecast amid challenges with BetterHelp insurance shift

Teladoc Health has lowered its 2026 revenue forecast due to unexpected pressure on its BetterHelp virtual behavioral health unit. The company is transitioning BetterHelp from a cash-pay to an insurance-covered model, but consumer demand for insurance-based services is outpacing clinical capacity, leading to a …

Teladoc Stock Plummets on Revenue Miss, Lowered Outlook

Teladoc Health Inc (NYSE:TDOC) saw its shares plunge by 22% after reporting second-quarter revenues that missed Wall Street estimates and subsequently lowering its full-year guidance. Despite a smaller-than-expected loss per share, investors reacted negatively to slowing growth in its BetterHelp mental health segment. The …

Teladoc Health Q2 Loss Widens, Revenue Falls; 2026 Guidance Updated

Teladoc Health Inc. reported a widening loss and a decrease in revenue for its second quarter of 2026, compelling the company to update its full-year 2026 guidance. This financial performance has led to a tumble in Teladoc's stock, primarily due to shifts in demand …

TELA Bio Inc (TELA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of TELA Bio Inc (TELA), noting its current valuation score of 8.99, which ranks it 50th out of 199 in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -0.85, noting its position …

Teladoc Health sinks 21% after mixed quarter and soft outlook (TDOC:NYSE)

Teladoc Health (TDOC) shares dropped 21% in premarket trading after reporting a mixed quarterly performance and issuing a Q3 outlook that missed Wall Street expectations. The company's CEO, Charles Divita, indicated that advertising spending for 2026 is now expected to be lower than previously …

Teladoc Health, Inc. Stock 12‑Month Price Target Raised to $7.84, Implies 15% Downside

Teladoc Health, Inc.'s average 12-month price target has modestly increased to $7.84 from $7.76, based on estimates from 19 analysts, with a range of $5 to $11. This updated target suggests a potential 15% downside from its July 29 closing price. The consensus rating …

Teladoc (TDOC) Stock Plummets on Disappointing Q2 Earnings Results

Teladoc Health (NYSE: TDOC) Q2 2026 shows revenue dip and weaker BetterHelp

TELA Bio Inc (TELA) Risk Assessment: Volatility, Financial Risk & Investment Risk

TELA Bio Inc (TELA) currently holds a risk assessment score of 2.60, positioning it 148th out of 199 companies in the Healthcare Equipment & Supplies industry. The stock exhibits a beta value of 1.30, indicating higher volatility compared to the S&P 500 index. The …

TELA Bio Inc (TELA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of TELA Bio Inc (TELA), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 5.52 and is trading between a resistance level …

TELA Bio to present at Canaccord Genuity Growth Conference on August 12, 2026

TELA Bio, a medical technology company focused on soft-tissue reconstruction, announced its upcoming presentation at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The presentation will be available via live and archived webcast, offering investors insights into the company's innovations and …

Teladoc Leans Toward Insurance-Pay as Larger Part of Revenue Mix, Driven by BetterHelp

Teladoc (NYSE: TDOC) is shifting its BetterHelp revenue mix towards insurance-pay as consumer demand for insurance-covered mental health services outpaces clinician capacity in some markets, leading to a decline in cash-pay revenue. This shift resulted in a 5% reduction in Teladoc's consolidated revenue guidance …

Teladoc Health | 8-K: Teladoc Health Reports Second Quarter 2026 Results

This document indicates that Teladoc Health has filed an 8-K report with the SEC. The report details the company's financial results for the second quarter of 2026. Further specific financial data would be found within the 8-K filing itself.

TELA Bio's Aug. 12 Conference Presentation Will Stream Live

TELA Bio (NASDAQ: TELA) announced its participation in the Canaccord Genuity 46th Annual Growth Conference, where company management is scheduled to present on August 12, 2026, at 8:30 a.m. ET. A live and archived webcast of the presentation will be available on the company's …

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

TELA Bio, Inc. (NASDAQ: TELA), a medical technology company, announced its participation in the Canaccord Genuity 46th Annual Growth Conference. Management is scheduled to present on August 12, 2026, at 8:30 am ET. A live and archived webcast of the presentation will be available …

TELA|TELA Bio Inc|Price:0.653|Chg%:-0.025

TELA Bio Inc (TELA) has a relatively healthy financial outlook with significant growth potential, although its stock price is expected to trend down in the medium term despite strong fundamentals. The company, a commercial-stage medical technology firm specializing in soft-tissue reconstruction, is considered fairly …

Teladoc Health (TDOC) Stock Still Looks Undervalued After a 94% Five Year Fall

Teladoc Health (TDOC) stock appears undervalued despite a significant 94% decline over the past five years. Both Discounted Cash Flow (DCF) analysis and market multiples suggest upside potential, with the DCF model indicating a 37.0% discount to intrinsic value. The company's future hinges on …

Teladoc (NYSE:TDOC) Misses Q2 CY2026 Revenue Estimates, Stock Drops 24.1%

Teladoc Lowers BetterHelp Outlook After Cash-Pay Revenue Falls

Teladoc (TDOC) Reports Q2 Loss, Lags Revenue Estimates

Teladoc (TDOC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Teladoc Health (TDOC) Releases Q2 2026 Earnings: Revenue Misses Estimates but EPS Improves

Teladoc Health (TDOC) reported Q2 2026 revenue of $606.9 million, missing estimates, while its net loss of $(0.21) per diluted share improved compared to the prior year and beat estimates. The company's financials also detail insider trading activity with 18 sales and no purchases …

Teladoc (TDOC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Seeking Clues to Teladoc (TDOC) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Teladoc Health Launches Person-Centered Virtual Care Platform for Connected Care

Teladoc Health has introduced Teladoc One, a new virtual care platform focused on personalized, coordinated healthcare by integrating primary, chronic disease, mental health, and acute care. The platform uses its Pulse intelligence engine to unify patient data, enabling multidisciplinary care teams and an AI …

Teladoc Health Canada achieves Accreditation Canada Primer Award

Teladoc Health Canada has received the Accreditation Canada Primer Award, validating its dedication to providing safe, high-quality, and patient-centered virtual and hybrid care. This achievement marks a significant milestone in Teladoc's commitment to clinical excellence and continuous improvement, especially as it helps to advance …

TELA Bio Inc (TELA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of TELA Bio Inc (TELA), listing its major shareholders and institutional holdings. Key shareholders include EW Healthcare Partners, Nantahala Capital Management, LLC, and North Run Capital, LP, along with a breakdown by shareholder type such as hedge funds …

TELA Bio Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance | TradingKey

This article provides a detailed profile of TELA Bio, Inc., a commercial-stage medical technology company focused on soft-tissue reconstruction. It covers the company's background, business scope, key products like the OviTex Reinforced Tissue Matrix and OviTex PRS, financial data, and market performance. The profile …

TELA|TELA Bio Inc|Price:0.904|Chg%:+0.164

TELA Bio Inc Balance Sheet Analysis (TELA)

This article provides a detailed quarterly and annual balance sheet analysis for TELA Bio Inc (TELA), including key financial metrics like cash, assets, liabilities, and shareholders' equity over recent fiscal quarters and years. It highlights changes in these figures, such as cash and cash …

TELA Bio Inc (TELA) Income Statement

This article provides the quarterly and annual income statements for TELA Bio Inc (TELA), detailing key financial metrics such as total revenue, cost of revenue, operating expenses, and net income over several fiscal years and quarters. It also includes frequently asked questions (FAQs) about …

TDOC|Teladoc Health Inc|Price:8.911|Chg%:+0.141

This article provides a comprehensive stock analysis of Teladoc Health Inc (TDOC), highlighting its strong fundamentals and significant growth potential, despite being considered fairly valued within its industry. It notes high institutional ownership and a recent "Hold" rating from multiple analysts, with expectations for …

Is Teladoc Health (TDOC) Undervalued As Teladoc One Tests The AI Health Threat?

Teladoc Health (TDOC) is gaining attention after launching Teladoc One, an AI-supported virtual care platform, amidst discussions around the impact of AI in healthcare. Despite a strong recent share price rebound of 52.52% over 90 days and 24.40% year-to-date, its five-year return is down …